Novartis | NVS - Current Assets


Novartis reported $30.46B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bausch Health Companies USD 5.98B 179M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Canopy Growth CAD 524.67M 78.85M Dec/2025
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Drreddys Laboratories INR 3.31B 164.26M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
J&J USD 59.17B 3.55B Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Phibro Animal Health USD 894.07M 31.88M Mar/2026
Prestige Brands USD 431.48M 1.94M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026
Sanofi EUR 30.95B 8.99B Dec/2025
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
Zoetis USD 6.47B 294M Mar/2026